Table 5.
Total number of events within 365 days follow-up in a cohort of patients acutely hospitalized with asthma (n = 1023), stratified by suPAR quartiles and blood eosinophil count
| suPAR | ||||
|---|---|---|---|---|
| Blood Eosinophils | 1st Quartile | 2nd Quartile | 3rd Quartile | 4th Quartile |
| Low (N)* | 109 | 104 | 92 | 147 |
| No event, N (%) | 61 (56.0) | 42 (40.4) | 51 (55.4) | 50 (34.0) |
| Readmitted†, N (%) | 47 (43.1) | 59 (56.7) | 35 (38.0) | 66 (44.9) |
| Mortality, N (%) | 1 (0.9) | 3 (2.9) | 6 (6.5) | 31 (21.1) |
| Intermediate (N)* | 67 | 52 | 60 | 58 |
| No event, N (%) | 40 (59.7) | 30 (57.7) | 25 (41.7) | 21 (36.2) |
| Readmitted†, N (%) | 27 (40.3) | 21 (40.4) | 33 (55.0) | 32 (55.2) |
| Mortality, N (%) | 0 (0) | 1 (1.9) | 2 (3.3) | 5 (8.6) |
| High (N)* | 101 | 98 | 68 | 67 |
| No event, N (%) | 70 (69.3) | 72 (73.5) | 36 (52.9) | 30 (44.8) |
| Readmitted†, N (%) | 30 (29.7) | 26 (26.5) | 31 (45.6) | 34 (50.7) |
| Mortality, N (%) | 1 (0.9) | 0 (0) | 1 (1.5) | 3 (4.5) |
*This analysis only included patients with full 365 days follow-up and blood eosinophil results available (n = 1023)
†Only including readmission events in patients without consequent death in the duration of the follow-up period
suPAR quartile cut-offs: Q1: < 1.9 ng/mL (n = 282), Q2: 1.9–2.6 ng/mL (n = 266), Q3: 2.61–3.5 ng/mL (n = 237), Q4: > 3.5 ng/mL (n = 283)
Blood eosinophil count cut-offs defined as Low (< 150 cells/μL, n = 452), Medium (150–300 cells/μL, n = 237), and High (> 300 cells/μL, n = 334)
suPAR – Soluble urokinase plasminogen activator receptor